News
ATOS
1.290
0.00%
0.000
Weekly Report: what happened at ATOS last week (0311-0315)?
Weekly Report · 21h ago
Atossa Therapeutics Appoints Dr. Cigler, Expands Board Governance
TipRanks · 6d ago
Press Release: Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. To its Board of Directors. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City. Atossa is a clinical stage biopharmaceutical company developing innovative medicines with a focus on breast cancer.
Dow Jones · 6d ago
*Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors
Dow Jones · 6d ago
Weekly Report: what happened at ATOS last week (0304-0308)?
Weekly Report · 03/11 10:40
Press Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting in 2024. The study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with breast cancer. Data from the 40mg run-in cohort of the ongoing Phase 2 study will be presented at the AACR Annual Meeting.
Dow Jones · 03/06 13:30
Thales posts higher profit, tackles weak telecom satellite market
NASDAQ · 03/05 06:22
Weekly Report: what happened at ATOS last week (0226-0301)?
Weekly Report · 03/04 10:42
Weekly Report: what happened at ATOS last week (0219-0223)?
Weekly Report · 02/26 10:52
Weekly Report: what happened at ATOS last week (0212-0216)?
Weekly Report · 02/19 10:54
Atossa spikes as H.C. Wainwright starts at Buy on lead asset
H.C. Wainwright launches coverage of Atossa Therapeutics with a Buy rating and a $4 per share target. The analyst cites the prospects of the company's lead asset, Z-Endoxifen. The company's shares are trading near cash levels, implying no value for its pipeline.
Seeking Alpha · 02/12 18:27
Atossa Therapeutics Price Target Announced at $4.00/Share by HC Wainwright & Co.
Dow Jones · 02/12 12:49
Atossa Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 02/12 12:49
HC Wainwright & Co. Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $4
Benzinga · 02/12 12:39
Weekly Report: what happened at ATOS last week (0205-0209)?
Weekly Report · 02/12 10:45
Atossa Therapeutics: A Promising Contender in Breast Cancer Therapy with Solid Financials
TipRanks · 02/08 19:16
Weekly Report: what happened at ATOS last week (0129-0202)?
Weekly Report · 02/05 10:52
Weekly Report: what happened at ATOS last week (0122-0126)?
Weekly Report · 01/29 10:44
Weekly Report: what happened at ATOS last week (0115-0119)?
Weekly Report · 01/22 10:47
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
Three biotech stocks with catalysts to propel their stock prices are Sarepta Therapeutics, Atossa and United. For many biotech stocks, the success of a drug in testing hinges on approval by the FDA. While biotech stocks reported lackluster performance in 2023, news of innovations and FDA decisions keep stock potential high.
Investorplace · 01/16 20:57
More
Webull provides a variety of real-time ATOS stock news. You can receive the latest news about Atossa Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.